Consolidated Financial Statements **December 31, 2015 and December 31, 2014**(expressed in US dollars)



March 9, 2016

### **Independent Auditor's Report**

To the Shareholders of EcoSynthetix Inc.

We have audited the accompanying consolidated financial statements of EcoSynthetix Inc. and its subsidiaries, which comprise the consolidated balance sheets as at December 31, 2015 and December 31, 2014 and the consolidated statements of operations and comprehensive loss, shareholders' equity and cash flows for the years then ended, and the related notes, which comprise a summary of significant accounting policies and other explanatory information.

### Management's responsibility for the consolidated financial statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with International Financial Reporting Standards, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

#### **Auditor's responsibility**

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with Canadian generally accepted auditing standards. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained in our audits is sufficient and appropriate to provide a basis for our audit opinion.



### **Opinion**

In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of EcoSynthetix Inc. and its subsidiaries as at December 31, 2015 and December 31, 2014 and their financial performance and their cash flows for the years then ended in accordance with International Financial Reporting Standards.

Pricewaterhouse Coopers U.P.

**Chartered Professional Accountants, Licensed Public Accountants** 

**Consolidated Balance Sheets** 

At December 31

(expressed in US dollars)		
	2015	2014
Assets		
Current assets Cash Accounts receivable (note 5) Inventory (note 6) Government grants receivable (note 7) Prepaid expenses	60,717,658 1,177,719 3,290,238 528,436 242,983	67,245,970 2,258,151 5,497,944 66,957 286,288
	65,957,034	75,355,310
Non-current assets Intangible assets (note 8) Property, plant and equipment (note 9)	8,746,072	52,683 11,690,072
Total assets	74,703,106	87,098,065
Liabilities		
Current liabilities Trade payables and accrued liabilities (note 10) Accrued termination benefits (note 11)	1,262,709 1,277,755	1,571,976
Total liabilities	2,540,464	1,571,976
Shareholders' Equity		
Common shares (note 14)	493,182,209	492,041,244
Contributed surplus	8,017,907	8,101,831
Accumulated deficit	(429,037,474)	(414,616,986)
Total shareholders' equity	72,162,642	85,526,089
Total liabilities and shareholders' equity	74,703,106	87,098,065

# Approved by the Board of Directors

(signed)	(signed)
John E. Barker, Chairman	Jeff MacDonald, Chief Executive Officer

Consolidated Statements of Operations and Comprehensive Loss For the years ended December 31

(expressed in US dollars)		
	2015	2014
Net sales	14,582,820	18,841,745
Cost of sales	12,500,455	15,671,096
Gross profit on sales	2,082,365	3,170,649
Expenses Selling, general and administrative Provision for termination benefits Research and development Impairment loss on property, plant & equipment (note 2)	8,488,594 1,939,080 3,870,552 2,500,000 16,798,226	12,210,214 236,473 5,569,632 - 18,016,319
Loss from operations	(14,715,861)	(14,845,670)
Interest income	295,373	331,081
Net loss and comprehensive loss	(14,420,488)	(14,514,589)
Basic and diluted loss per common share (note 19)	(0.25)	(0.26)
Weighted average number of common shares outstanding	57,977,096	56,656,036

Consolidated Statements of Shareholders' Equity

For the years ended December 31

(expressed in US dollars)

	Common shares	Contributed surplus	Accumulated deficit	Total
Balance - January 1, 2014	492,600,022	7,661,849	(400,102,397)	100,159,474
Warrants exercised (note 14) Common share options exercised (note 13) Share-based compensation (note 13) Common shares repurchased Net loss and comprehensive loss	160,058 43,948 - (762,784) -	(16,018) 456,000 - -	- - - - (14,514,589)	160,058 27,930 456,000 (762,784) (14,514,589)
Balance - December 31, 2014	492,041,244	8,101,831	(414,616,986)	85,526,089
Balance - January 1, 2015	492,041,244	8,101,831	(414,616,986)	85,526,089
Common share options exercised (note 13) Share-based compensation (note 13) Net loss and comprehensive loss	1,140,965 - -	(497,047) 413,123	- (14,420,488)	643,918 413,123 (14,420,488)
Balance - December 31, 2015	493,182,209	8,017,907	(429,037,474)	72,162,642

Consolidated Statements of Cash Flows

# For the years ended December 31

(expressed in US dollars)	
---------------------------	--

(expressed in US dollars)		
	2015	2014
Cash provided by (used in)		
Operating activities  Net loss and comprehensive loss  Items not affecting cash  Depreciation, amortization and impairment loss of	(14,420,488)	(14,514,589)
property, plant & equipment (notes 2, 8 and 9) Share-based compensation (note 13) Unrealized foreign exchange loss Other	3,945,407 413,123 139,937 796,115	1,767,366 456,000 - -
Changes in non-cash working capital Accounts receivable Inventory Government grants receivable (note 7) Prepaid expenses Accounts payable and accrued liabilities Accrued termination benefits	1,080,432 2,139,842 (917,228) 43,305 (409,267) 1,277,755	1,433,640 787,338 194,691 (9,432) (2,375,409)
	(5,911,067)	(12,260,395)
Investing activities Purchase of property, plant and equipment (note 9)	(780,860)	(425,796)
Financing activities Proceeds from government grant Exercise of common share options Repurchase of common shares Exercise of warrants	455,749 643,918 - -	- 27,930 (762,784) 160,058
	1,099,667	(574,796)
Effect of exchange rate changes on cash	(936,052)	
Decrease in cash during the year	(6,528,312)	(13,260,987)
Cash - Beginning of year	67,245,970	80,506,957
Cash - End of year	60,717,658	67,245,970

Notes to Consolidated Financial Statements

December 31, 2015 and December 31, 2014

(expressed in US dollars, unless otherwise noted)

## 1 Business operations

EcoSynthetix Inc. (EcoSynthetix or the Company) is engaged in the development and commercialization of ecologically friendly, bio-based technologies as replacement solutions for synthetic, petrochemical-based adhesives and other related products in the Americas, Europe, Middle East and Africa (EMEA), and Asia Pacific. EcoSynthetix is incorporated and domiciled in Canada. The address of its registered office is 3365 Mainway, Burlington, Ontario, Canada.

### 2 Summary of significant accounting policies

### Statement of compliance

These consolidated financial statements have been authorized for issuance by the Board of Directors of the Company on March 7, 2016.

#### **Basis of preparation**

The consolidated financial statements have been prepared under International Financial Reporting Standards (IFRS), using the historical cost convention except for liabilities related to share-based payment arrangements that are measured at fair value.

### Use of estimates and judgments

The preparation of consolidated financial statements in accordance with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. These estimates are based on management's best knowledge of current events and actions that the Company may undertake in the future. Actual results may differ from those estimates.

Significant estimates made by the Company include estimates of useful lives of property, plant and equipment, share-based compensation, potentially uncollectible accounts receivable, provisions for inventory that are carried in excess of net realizable value and the realizability of deferred income tax assets.

Property, plant and equipment and intangible assets are tested for impairment at the end of each reporting period or when events or changes in circumstances indicate the carrying amount may not be recoverable. For the purpose of measuring recoverable amounts, assets are grouped at the lowest levels for which there are separately identifiable cash in-flows (cash-generating units or CGUs). The recoverable amount is the higher of an asset's fair value less costs to sell and value in use (which is the present value of the expected future cash flows of the relevant asset or CGU). An impairment loss is recognized for the amount by which the asset's carrying amount exceeds its recoverable amount. Non-financial assets that have been impaired previously are reviewed for possible reversal of impairment at each reporting date.

The Company has determined it has a single CGU, assessed as the entity as a whole, due to the interdependence of the Company's assets and liabilities in generating cash inflows. The recoverable amount of the CGU is highly dependent upon projected revenues, expenses and discount rates used in performing an analysis.

Notes to Consolidated Financial Statements

December 31, 2015 and December 31, 2014

(expressed in US dollars, unless otherwise noted)

As at December 31, 2015 the Company determined that indication of impairment existed primarily due to the value of the Company's net assets exceeding the market capitalization of the Company and on-going operating losses. The Company performed an impairment assessment as at December 31, 2015 and has recorded an impairment charge of \$2.5 million in relation to its property plant and equipment (note 9).

In determining the recoverable amount of the CGU, the Company used a value in use analysis having concluded that due to the measurement uncertainty related to valuing the Company's future growth it was not possible to accurately determine a point estimate of the fair value less cost to sell of the CGU.

### **Basis of consolidation**

The consolidated financial statements of the Company consolidate the accounts of EcoSynthetix and all of its subsidiaries. All intercompany transactions, balances and unrealized gains and losses from intercompany transactions are eliminated on consolidation.

Subsidiaries are all entities wholly owned and controlled by the Company.

#### Foreign currency translation

i) Functional and presentation currency

Items included in the financial statements of each consolidated entity in the Company's consolidated financial statements are measured using the currency of the primary economic environment in which the entity operates (the functional currency). The consolidated financial statements are presented in US dollars, which is the Company's reporting currency. The functional currency of all entities is US dollars.

ii) Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign currency exchange gains and losses resulting from the settlement of foreign currency transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in currencies other than the Company's functional currency are recognized in the consolidated statements of operations and comprehensive loss.

### Cash

Cash consists of deposits held with banks.

### **Trade receivables**

Trade receivables are amounts due from customers for products sold in the ordinary course of business. If collection is expected in one year or less, they are classified as current assets.

Trade receivables are recognized initially at fair value and subsequently measured at amortized cost using the effective interest method, less a provision for impairment.

Notes to Consolidated Financial Statements

December 31, 2015 and December 31, 2014

(expressed in US dollars, unless otherwise noted)

### **Financial instruments**

Financial assets and financial liabilities are recognized when the Company becomes a party to the contractual provisions of the financial instrument. Financial assets are derecognized when the rights to receive cash flows from the financial assets have expired or have been transferred and the Company has transferred substantially all risks and rewards of ownership.

Financial assets and financial liabilities are offset and the net amount reported in the consolidated balance sheets when there is a legally enforceable right to offset the recognized amounts and there is an intention to settle on a net basis, or realize the financial asset and settle the financial liability simultaneously.

At initial recognition, the Company classifies its financial instruments in the following categories, depending on the purpose for which the financial instruments were acquired:

### i) Loans and receivables

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. The Company's loans and receivables comprise accounts receivable, government grants receivable and cash and are classified as current, except for the portion expected to be realized or paid beyond 12 months of the consolidated balance sheet dates, which is classified as non-current. Loans and receivables are initially recognized at the amount expected to be received less, when material, a discount to reduce the loans and receivables to fair value. Subsequently, loans and receivables are measured at amortized cost using the effective interest method, less a provision for impairment.

#### ii) Financial liabilities at amortized cost

Financial liabilities at amortized cost include trade payables and accrued liabilities. Trade payables and accrued liabilities are initially recognized at the amount required to be paid less, when material, a discount to reduce the payables to fair value. Subsequently, trade payables and accrued liabilities are measured at amortized cost, using the effective interest method.

Financial liabilities are classified as current liabilities if payment is due within 12 months. Otherwise, they are presented as non-current liabilities.

### Impairment of financial assets

At each reporting date, the Company assesses whether there is objective evidence that a financial asset is impaired. If such evidence exists, the Company recognizes an impairment loss on financial assets carried at amortized cost. The loss is the difference between the amortized cost of the receivable and the present value of the estimated future cash flows, discounted using the financial instrument's original effective interest rate. The carrying amount of the asset is reduced by this amount either directly or indirectly through the use of an allowance account.

Notes to Consolidated Financial Statements

December 31, 2015 and December 31, 2014

(expressed in US dollars, unless otherwise noted)

Impairment losses on financial assets carried at amortized cost are reversed in subsequent years if the amount of the loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognized.

### **Inventory**

Inventory is valued at the lower of cost, determined on a first-in, first-out basis, and net realizable value. Inventory costs include the costs of material, labour, variable overhead and an allocation of fixed manufacturing overhead, including depreciation based on normal production volumes. Net realizable value is the estimated selling price less applicable selling expenses.

### Property, plant and equipment

Property, plant and equipment are stated at cost less accumulated depreciation and accumulated impairment losses. Cost includes expenditures that are directly attributable to the acquisition of the asset. Subsequent costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost can be measured reliably. The carrying amount of a replaced asset is derecognized when replaced. Repairs and maintenance costs are charged to the consolidated statements of operations and comprehensive loss during the year in which they are incurred.

Depreciation is calculated on a straight-line method to reduce the cost of the asset to its residual value over its estimated useful life. The depreciation period applicable to each category of property, plant and equipment is as follows:

Leasehold improvements Computer hardware Machinery and equipment remaining lease term 3 years 2 to 15 years

Useful lives and residual values are reviewed and adjusted, if appropriate, at the end of each reporting period.

An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount. Gains and losses on disposals of property, plant and equipment are determined by comparing the proceeds with the carrying amount of the asset and are included as part of other gains and losses in the consolidated statements of operations and comprehensive loss.

### **Intangible assets**

Computer software costs are amortized on a straight-line basis over their estimated useful lives, which are approximately three years.

Notes to Consolidated Financial Statements

December 31, 2015 and December 31, 2014

(expressed in US dollars, unless otherwise noted)

### **Provisions**

Provisions are recognized when the Company has a present legal or constructive obligation as a result of past events, it is more likely than not that an outflow of resources will be required to settle the obligation, and the amount can be reliably estimated. Provisions are measured at management's best estimate of the expenditure required to settle the obligation at the end of the reporting period and are discounted to present value where the effect is material. The Company performs evaluations to identify onerous contracts and, where applicable, records provisions for such contracts.

### Research and product development costs

Expenditures during the research phase are expensed as incurred. Expenditures during the development phase are expensed as incurred, unless it is probable that future economic benefits that are attributable to the asset will flow to the Company; and the cost of the asset can be measured reliably. No development costs have been capitalized to date.

### **Government grants**

Government grants include funding for government research and product development support. Research and product development funding is recognized when there is reasonable assurance the Company has complied with the conditions attached to the funding arrangement and is recognized as the applicable costs are incurred. Research and product development funding is presented as a reduction in research and product development expenses, unless it is for the reimbursement of an asset, in which case, it is accounted for as a reduction in the carrying amount of the applicable asset.

### **Revenue recognition**

Revenue is recognized when the Company has transferred the significant risks and rewards of ownership of the goods to the buyer, it is probable that the economic benefits will flow to the Company, delivery has occurred, and the amount of revenue and costs incurred or to be incurred can be measured reliably. These criteria are generally met at the time the product is shipped and the risks and rewards have passed to the customer. Revenue is measured based on the price specified in the sales contract, net of discounts and estimated returns at the time of sale. Historical experience is used to estimate and provide for discounts and returns.

### Cost of sales and gross profit

Gross profit is derived from net sales, less cost of sales. Cost of sales includes raw material costs, contract manufacturing costs, freight costs and depreciation related to manufacturing equipment. Raw materials consist of the costs of natural feedstock and process chemicals.

### Share capital

Common shares are classified as equity. Incremental costs directly attributable to the issuance of common shares are recognized as a deduction from shareholders' equity. The Company has classified all outstanding exchangeable shares of its subsidiaries as issued and outstanding of the parent company.

Notes to Consolidated Financial Statements

December 31, 2015 and December 31, 2014

(expressed in US dollars, unless otherwise noted)

### **Share-based compensation**

The Company operates equity-settled share-based compensation plans under which the Company receives services from employees, advisers, officers, directors, contractors and consultants as consideration for equity instruments (share options, performance-based share options (PSOs), restricted share units (RSUs) and deferred share units (DSUs)) of the Company.

Each tranche of a share option award is considered a separate award with its own vesting period and recorded at fair value on the date of grant. The fair value of each tranche is measured at the date of grant using the Black-Scholes option pricing model. Compensation expense is recognized over the tranche's vesting period based on the number of awards expected to vest by increasing contributed surplus. The number of awards expected to vest is reviewed periodically with any impact being recognized in the consolidated statements of operations and comprehensive loss. Any contribution paid by an employee or director on the exercise of share options is credited to common shares with any previously recognized compensation expense.

A PSO provides a right, but not an obligation, to purchase common shares of the Company at a stated price for a given period of time. PSOs vest at a rate of 33.33% per year following the grant date subject to the achievement of performance hurdles and can only be settled in common shares issued from treasury. In the event that performance exceeds targeted performance hurdles, vesting can accelerate for PSOs granted; however, in no event can the cumulative vesting exceed 100%. All PSOs have an expiry between seven and ten years. The fair values of PSOs are recorded over the expected vesting period, subject to management's estimate of the achievement of the performance hurdles. The fair values of the PSOs are recognized as compensation expense over the vesting period with a corresponding increase to contributed surplus. The exercise price is determined based on the average closing price of common shares on the Toronto Stock Exchange (TSX) five trading days immediately prior to the date as of which fair value is determined. The Company has estimated the length of the expected vesting period at grant date based on the most likely outcome of the performance conditions. The Company will revise its estimate of the length of the vesting period, if necessary, if subsequent information indicates that the length of the vesting period differs from previous estimates and any change to compensation cost will be recognized in the period in which the revised estimate is made. Forfeitures are estimated at the grant date and are revised to reflect a change in expected or actual forfeitures.

The restricted share unit plan (RSU Plan) provides that restricted share unit awards (the RSUAs) may be granted by a committee that administers the RSU Plan to full-time employees, officers and eligible contractors of the Company or an affiliate in a calendar year as a bonus for services rendered to the Company as determined at the sole discretion of the Board. The number of RSUs awarded will be credited to the participants' accounts effective on the grant date of the RSUs. Each RSUA entitles the holder to receive common shares issued from the treasury of the Company. RSUs fully vest at the end of a three-year period subject to continued employment with the Company and the achievement of performance hurdles. The Company has estimated the probability of achieving the performance hurdles and will revise its estimate if subsequent information indicates that the expected outcome related to the achievement of the performance hurdles differs from previous estimates. Accordingly, any change to compensation cost will be recognized in the period in which the revised estimate is made. Forfeitures are estimated at the grant date and are revised to reflect a change in expected or actual forfeitures.

Notes to Consolidated Financial Statements

December 31, 2015 and December 31, 2014

(expressed in US dollars, unless otherwise noted)

The deferred share unit plan (DSU Plan) provides for awards of DSUs to non-employee directors of the Company. Under the DSU Plan, non-executive directors may receive a grant of DSUs in satisfaction of their annual retainer. Each DSU is equivalent to one common share and vests on a quarterly basis. DSUs must be retained until the director leaves the Board, at which time the DSUs will be settled through common shares. In the event dividends are declared and paid, additional DSUs would be credited to reflect dividends paid on common shares. The number of DSUs to be awarded is determined based on the average closing price of the common shares on the TSX on five trading days immediately prior to the date as of which fair value is determined. Compensation cost for DSUs granted under the DSU Plan is recorded as an expense with a corresponding increase in contributed surplus.

#### **Income taxes**

Income taxes comprise current and deferred income taxes. Income taxes are recognized in the consolidated statements of operations and comprehensive loss, except to the extent that they relate to items recognized directly in shareholders' equity, in which case the income taxes are also recognized directly in shareholders' equity.

Current income taxes are the expected income taxes payable on the taxable income for the year, using income tax rates enacted or substantively enacted, at the end of the reporting period, and any adjustment to income taxes payable in respect of previous years.

In general, deferred income taxes are recognized in respect of temporary differences arising between the income tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred income taxes are determined on a non-discounted basis using income tax rates and laws that have been enacted or substantively enacted at the consolidated balance sheet dates and are expected to apply when the deferred income tax asset or liability is settled. Deferred income tax assets are recognized to the extent that it is probable that the assets can be recovered.

Deferred income taxes are provided on temporary differences arising on investments in subsidiaries and associates, except, in the case of subsidiaries, where the timing of the reversal of the temporary difference is controlled by the Company and it is probable that the temporary difference will not reverse in the foreseeable future.

Deferred income tax assets and liabilities are presented as non-current.

### Loss per share

Basic loss per common share is calculated based on the weighted average number of common shares outstanding for the year. Diluted loss per common share is calculated using the weighted average number of common shares outstanding for the year for basic net loss per common share plus the weighted average number of potential dilutive common shares that would have been outstanding during the year had potentially all common shares been issued at the beginning of the year or when the underlying share options or warrants were granted, if later, unless they were anti-dilutive.

Notes to Consolidated Financial Statements

December 31, 2015 and December 31, 2014

(expressed in US dollars, unless otherwise noted)

### **Operating leases**

Leases in which a significant portion of the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments under an operating lease (net of any incentives received from the lessor) are recognized in the consolidated statements of operations and comprehensive loss on a straight-line basis over the period of the lease.

### **Operating segments**

The Company operates in one operating segment that is reported in a manner consistent with the internal reporting provided to the chief operating decision-maker (CODM). The chief executive officer has authority for resource allocation and assessment of the Company's performance and is, therefore, the CODM.

#### New accounting standards

Standards issued but not yet effective or amended up to the date of issuance of the Company's consolidated financial statements are listed below. This listing is of standards and interpretations issued, which the Company reasonably expects to be applicable at a future date. The Company has not determined if they will early adopt any standards at this time.

- a) In July 2014, the IASB issued the final version of IFRS 9, Financial Instruments which reflects all phases of the financial instruments project and replaces IAS 39, Financial Instruments - Recognition and Measurement and all previous versions of IFRS 9. The standard introduces new requirements for classification and measurement, impairment, and hedge accounting. IFRS 9 is effective for annual periods beginning on or after January 1, 2018, with early application permitted. Retrospective application is required, but comparative information is not compulsory. The Company is evaluating the impact of adopting the new standard.
- b) In May 2014, the IASB issued IFRS 15, Revenue from Contracts with Customers, which establishes a single comprehensive model of accounting for revenue arising from contracts with customers that an entity will apply to determine the measurement of revenue and timing of when it is recognized. IFRS 15 supersedes current revenue recognition guidance, which is found currently across several standards and interpretations including IAS 11, Construction Contracts and IAS 18, Revenue. The core principle of IFRS 15 is that an entity recognizes revenue to depict the transfer of promised goods and services to customers in an amount that reflects the amount an entity expects to be entitled to in exchange for those goods and services. The new standard will also result in enhanced disclosures about revenue that would result in an entity providing comprehensive information about the nature, amount, timing and uncertainty of revenue and cash flows arising from the entity's contracts with customers. On April 28, 2015, the IASB voted to publish an Exposure Draft proposing a one-year deferral of the effective date of this standard to January 1, 2018. The Company has not yet assessed the impact of the adoption of this standard on its consolidated financial statements.

Notes to Consolidated Financial Statements

December 31, 2015 and December 31, 2014

(expressed in US dollars, unless otherwise noted)

- c) On January 13, 2016, the IASB issued IFRS 16, Leases, which will replace IAS 17, Leases. The new standard will be mandatorily effective for fiscal years beginning on or after January 1, 2019. Earlier application is permitted. Under the new standard, all leases will be on the balance sheet of lessees, except those that meet limited exception criteria. The Company has not yet assessed the impact of the adoption of this standard on its consolidated financial statements.
- d) In the 2012 2014 annual improvements cycle, the IASB issued four amendments to four standards, which included an amendment to IFRS 5, Non-current Assets Held for Sale and Discontinued Operations, to add specific guidance for cases in which an entity reclassifies an asset from held for sale to held for distribution or vice versa and cases in which held-for-distribution accounting is discontinued. An amendment was made to IFRS 7, Financial Instruments Disclosures, to clarify whether a servicing contract is continuing involvement in a transferred asset, and clarification on offsetting disclosures in condensed interim financial statements. An amendment was made to IAS 34, Interim Financial Reporting, to clarify the meaning of 'elsewhere in the interim report' and require a cross-reference. These amendments are applicable to annual periods beginning on or after July 1, 2016. The Company has not yet assessed the impact of these amendments on its consolidated financial statements.

### 3 Risk management and financial instruments

The Company has classified its financial instruments into one of the following categories: loans and receivables and other financial liabilities at amortized cost. The following table summarizes information regarding the carrying amounts of the Company's financial instruments:

	2015	2014
Loans and receivables	62,423,813	69,571,078
Other financial liabilities	2,540,464	1,571,976

## Liquidity

The Company has sustained losses and negative cash flows from operations since its inception. Liquidity risk is the risk the Company will encounter difficulty in meeting its financial obligations associated with financial liabilities that are settled by delivering cash or another financial asset. The Company is exposed to liquidity risk as it continues to have net cash outflows to support its operations. The Company's approach to managing liquidity risk is to ensure it will have sufficient liquidity to meet liabilities when due. The Company achieves this by maintaining sufficient cash. The Company monitors its financial position on a monthly basis and updates its expected use of cash resources based on the latest available data. The Company's trade payables and accrued liabilities will be paid within the next 12 months.

Notes to Consolidated Financial Statements

December 31, 2015 and December 31, 2014

(expressed in US dollars, unless otherwise noted)

#### Credit risk

Credit risk arises from the potential that a counterparty will fail to perform its obligations. The Company is exposed to credit risk from customers. At December 31, 2015, the Company's three largest customers accounted for 73% (2014 - three customers at 54%) of accounts receivable. In order to minimize the risk of loss for accounts receivable, the Company's extension of credit to customers involves a review and approval by senior management. The majority of the Company's sales are invoiced with payment terms between three and 60 days. The Company's objective is to minimize its exposure to credit risk from customers in order to prevent losses on financial assets by performing regular monitoring of overdue balances and to provide an allowance for potentially uncollectible accounts receivable.

The Company's trade accounts receivable have a carrying amount of \$987,059 at December 31, 2015 (2014 - \$2,142,926), representing the maximum exposure to credit risk of those financial assets, exclusive of the allowance for doubtful accounts. An insignificant number of these receivables were past due at December 31, 2015. The Company's exposure to credit risk for trade accounts receivable by geographic area at December 31 was as follows:

	2015 %	2014 %
Americas	47	48
EMEA	9	2
Asia Pacific	44	50
	100	100

The Company may also have credit risk relating to cash, which it manages by dealing with large chartered Canadian and US banks. The Company's objective is to minimize its exposure to credit risk in order to prevent losses on financial assets by placing its investments in lower risk deposits of these chartered banks. The Company's cash carrying amount is \$60,717,658 at December 31, 2015 (2014 - \$67,245,970), representing the maximum exposure to credit risk of these financial assets. Approximately 99% (2014 - 99%) of the Company's cash at December 31, 2015 was held with one financial institution. The Company's exposure to credit risk relating to cash segmented by geographic area at December 31 was as follows:

	2015 %	<b>2014</b> %
Canada United States of America	98.8 0.7	99.3 0.5
The Netherlands	0.5	0.2
	100.0	100.0

Notes to Consolidated Financial Statements

December 31, 2015 and December 31, 2014

(expressed in US dollars, unless otherwise noted)

### Foreign currency risk

Foreign currency risk arises because of fluctuations in foreign currency exchange rates. The Company conducts a portion of its business activities in currencies other than the functional currency of the parent company (US dollars). This primarily includes Canadian dollar and euro denominated transactions. The Company's objective in managing its foreign currency risk is to minimize its net exposure to foreign currency cash flows by converting foreign denominated financial assets into US dollars to the extent practical to match the obligations of its financial liabilities. Financial assets and financial liabilities denominated in foreign currencies will be affected by changes in the exchange rate between the functional currency and these foreign currencies. This primarily includes cash, accounts receivable and trade payables and accrued liabilities, which are denominated in foreign currencies. The Company realized foreign currency exchange losses in the year ended December 31, 2015 of \$796,115 (2014 - \$223,000). The Company has unrealized foreign exchange losses in the year ended December 31, 2015 of \$139,937.

If a shift in the Canadian dollar relative to the US dollar of 10% were to occur, the foreign currency exchange gain or loss on the net financial assets would be \$484,807 (2014 - \$860,000) due to exchange rate fluctuations and this amount would be recorded in the consolidated statements of operations and comprehensive loss.

If a shift in the euro relative to the US dollar of 10% were to occur, the exchange gain or loss on the net financial assets would be nominal (2014 - not significant) due to exchange rate fluctuations and this amount would be recorded in the consolidated statements of operations and comprehensive loss.

#### Interest rate risk

Interest rate risk arises because of the fluctuation in market interest rates. The Company's objective in managing interest rate risk is to maximize the return on its cash. The Company is subject to interest rate risk on its cash. If a shift in interest rates of 10% were to occur, the impact on the consolidated statements of operations and comprehensive loss for the year would be a gain or loss of \$28,289 (2014 - \$33,673).

#### Fair value

The carrying amounts of accounts receivable and trade payables and accrued liabilities approximate their fair values given their short-term nature.

### Fair value measurement recognized in the consolidated balance sheets

Financial instruments that are measured at fair value are grouped into Levels 1 to 3, based on the degree to which their fair value is observable.

• Level 1 - Fair value measurements are those derived from quoted prices (unadjusted) in active markets for identical financial assets or financial liabilities.

Notes to Consolidated Financial Statements

#### December 31, 2015 and December 31, 2014

(expressed in US dollars, unless otherwise noted)

- Level 2 Fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the financial asset or financial liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).
- Level 3 Fair value measurements are those derived from valuation techniques that include inputs for the financial asset or financial liability that are not based on observable market data (unobservable inputs).

The Company's financial assets and liabilities at fair value as at December 31, 2015 were as follows:

	Level 1	Level 2	Level 3	Total
Cash	60,717,658	-	-	60,717,658
Accounts receivable Trade payables and accrued	-	1,177,719	-	1,177,719
liabilities	-	(2,540,464)	-	(2,540,464)
Government grants receivable		528,436	-	528,436
	60,717,658	(834,309)	-	59,883,349

The Company's financial assets and liabilities at fair value as at December 31, 2014 were as follows:

	Level 1	Level 2	Level 3	Total
Cash	67,245,970	-	-	67,245,970
Accounts receivable  Trade payables and accrued	-	2,258,151	-	2,258,151
liabilities	-	(1,571,976)	-	(1,571,976)
Government grants receivable		66,957	-	66,957
	67,245,970	753,132	-	67,999,102

During the year, there were no reclassifications into or out of Level 3.

## 4 Capital management

The Company's objective in managing capital is to ensure sufficient liquidity to pursue its growth strategy and fund research and product development, while at the same time, taking a conservative approach toward financial leverage and management of financial risk. The Company's capital is composed of total shareholders' equity. The total capital as at December 31, 2015 is \$72,162,642 (2014 - \$85,526,089). The Company's primary uses of capital are financing operations, increasing non-cash working capital and capital expenditures. The Company currently funds these requirements from existing cash resources and cash raised through share issuances. The Company's objectives when managing capital are to ensure the Company will continue to have enough liquidity so that it can provide its products and services to its customers and returns to its shareholders. The Company monitors its capital on the basis of the adequacy of its cash resources to fund its business plan. In order to maximize the capacity to finance the Company's ongoing growth, the Company does not currently pay a dividend to holders of its common shares.

Notes to Consolidated Financial Statements

December 31, 2015 and December 31, 2014

(expressed in US dollars, unless otherwise noted)

### 5 Accounts receivable

	2015	2014
Trade accounts receivable	987,059	2,142,926
Commodity taxes receivable and other	190,660	115,225
	1,177,719	2,258,151

During the year ended December 31, 2015, the Company recorded a bad debt expense of \$nil (2014 - \$400,000).

The aging of trade accounts receivable at each reporting date was as follows:

		2015	2014
	Current Past due 1 - 30 days Past due 31 - 60 days Past due 61 - 90 days	948,544 38,515 - -	2,075,244 45,421 22,261
	Past due greater than 91 days	<del>-</del>	
		987,059	2,142,926
6	Inventory		
		2015	2014
	Raw materials	678,855	945,644
	Finished goods	2,611,383	4,552,300
		3,290,238	5,497,944

The Company recorded a provision of \$0.2 million (2014 - \$nil) against finished goods and raw materials inventory.

### 7 Government grants

In September 2014, the Company announced that it would receive a grant of approximately \$2.0 million from Agriculture and Agri-Food Canada (AAFC) through a national Bioproducts cluster that was developed by BioIndustrial Innovation Canada (BIC) (the grant). The grant was provided in support of accelerated commercialization for new bio-based platforms targeting the replacement of non-renewable chemicals. The grant could be repayable in the event a condition of default occurs. The Company expects to comply with the conditions of the grant and has accordingly recognized this grant in its operating results during fiscal 2015.

Notes to Consolidated Financial Statements

December 31, 2015 and December 31, 2014

(expressed in US dollars, unless otherwise noted)

During the fiscal year ended December 31, 2015, the Company recorded CA\$1.2 million of grants of which CA\$1.0 million was recognized against operating expenses and CA\$0.2 million was recognized against property, plant and equipment. The company collected CA\$0.6 million of grants in cash during the year which resulted in CA\$0.6 million of government grants receivable outstanding as at December 31, 2015. The Company expects to collect this outstanding balance within the next 12 months.

## 8 Intangible assets

The composition of the net carrying amount of the Company's intangible assets is presented in the following table:

	Computer software
Cost December 31, 2014 Additions	417,850
December 31, 2015	417,850
Accumulated amortization December 31, 2014 Amortization	(365,167) (52,683)
December 31, 2015	(417,850)
Carrying amount December 31, 2014	52,683
December 31, 2015	

Amortization expense has been charged to selling, general and administrative expenses.

Notes to Consolidated Financial Statements

December 31, 2015 and December 31, 2014

(expressed in US dollars, unless otherwise noted)

## 9 Property, plant and equipment

The composition of the net carrying amount of the Company's property, plant and equipment is presented in the following table:

				Construction- in-process and deposits	
	Machinery and	Leasehold	Computer	placed on	
	equipment	improvements	hardware	property, plant and equipment	Total
Cost					
January 1, 2014	13,809,247	948,540	284,277	219,218	15,261,282
Additions Transfers	412,809 219,218	-	12,987 -	(219,218)	425,796 -
December 31, 2014	14,441,274	948,540	297,264	_	15,687,078
Additions	875,744	-	5,116	-	880,860
December 31, 2015	15,317,018	948,540	302,380	-	16,567,938
Accumulated depreciation and impairment loss (note 2)					
Ìanuarý 1, 2014	(2,046,853)	(256,761)	(182,480)	-	(2,486,094)
Depreciation	(1,340,301)	(120,045)	(50,566)	-	(1,510,912)
December 31, 2014	(3,387,154)	(376,806)	(233,046)	-	(3,997,006)
Depreciation expense Impairment loss (note 2)	(1,153,086) (2,069,984)	(141,718) (430,016)	(30,056)	-	(1,324,860) (2,500,000)
impairment ioss (note 2)	(2,009,904)	(430,010)			
December 31, 2015	(6,610,224)	(948,540)	(263,102)		(7,821,866)
Net carrying amount					
December 31, 2014	11,054,120	571,734	64,218	-	11,690,072
December 31, 2015	8,706,794	-	39,278	-	8,746,072

The Company invested \$880,860 (2014 - \$425,796) in capital asset additions for the year ended December 31, 2015, net of \$180,293 (2014 - \$nil) in government grants. The additions primarily relate to equipment for production and research and development purposes. \$100,000 of capital asset additions were included in trade payables and accrued liabilities as at December 31, 2015 (2014 - \$nil).

During the year ended December 31, 2015, depreciation expense of \$883,446 (2014 - \$1,023,689) has been charged to cost of goods sold and \$509,278 (2014 - \$614,936) has been charged to selling, general and administrative expenses.

Notes to Consolidated Financial Statements

#### December 31, 2015 and December 31, 2014

(expressed in US dollars, unless otherwise noted)

Trade payables and accrued liabilities

	2015	2014
Trade payables	489,464	802,449
Accrued liabilities	773,245	769,527
	1,262,709	1,571,976

#### 10 Termination benefits

During the year ended December 31, 2015, the Company recognized \$1.9 million in termination benefits as a result of a workforce reduction in addition to the termination of employment of the former Chief Executive Officer (former CEO) effective May 1, 2015.

### 11 Key management compensation

Key management personnel includes those individuals having authority and responsibility for planning, directing and controlling the activities of the Company directly or indirectly. Key management personnel includes the directors, chief executive officer, chief financial officer and other key members of the executive team. The compensation paid or payable to key management personnel for employee services is shown below:

	2015	2014
Salaries and other short-term employee benefits Share-based payments	1,480,936 427,306	2,026,113 329,171
	1,908,242	2,355,284

### 12 Shared-based compensation

At December 31, 2015, the Company had outstanding share options to purchase 4,350,952 common shares of the Company. The share options expire at various dates through January 1, 2025.

	Number of share options outstanding	Weighted average exercise price CA\$
Outstanding - December 31, 2013 Share options cancelled Share options granted Share options exercised	6,064,281 (144,016) 818,683 (287,959)	1.61 3.39 2.52 6.11
Outstanding - December 31, 2014 Share options cancelled Share options granted Share options exercised	6,450,989 (1,845,946) 2,483,861 (2,737,952)	1.75 2.97 1.39 0.30
Outstanding - December 31, 2015	4,350,952	2.02

Notes to Consolidated Financial Statements

December 31, 2015 and December 31, 2014

(expressed in US dollars, unless otherwise noted)

The weighted average contractual life of the outstanding share options at December 31, 2015 is 6.2 years (2014 - 5.01 years). The total number of share options exercisable at December 31, 2015 is 1,615,648 (2014 - 6,464,280), which have a weighted average exercise price of CA\$2.11 (2014 - CA\$1.12) per share.

	Number of share options outstanding	
	2015	2014
Range of exercise prices		
\$0.01 - \$0.50	-	1,906,002
\$0.51 - \$1.00	480,267	1,287,743
\$1.00 - \$1.50	2,160,174	206,496
\$1.50 - \$2.00	321,192	-
\$2.00 - \$2.50	-	-
\$2.50 - \$3.00	1,002,533	1,632,019
\$3.00 - \$3.50	265,444	511,113
\$3.50 - \$4.00	25,342	71,971
\$4.00 - \$4.50	-	678,415
\$4.50 - \$5.00	-	36,230
\$5.00 - \$5.50	24,500	49,500
\$5.50 - \$6.00	-	-
\$6.00 - \$6.50	-	-
\$6.50 - \$7.00	-	-
\$7.00 - \$7.50	71,500	71,500
	4,350,952	6,450,989

For the years ended December 31, the Company determined the fair values of share options using the Black-Scholes option pricing model with the following assumptions for share option grants:

	2015	2014
Expected dividend yield	-%	-%
Risk-free interest rate	1.05% - 1.33%	1.32 - 1.47%
Expected share option life (in years)	5	5
Volatility	56%	56%

The aggregate fair value of share options granted during the year is \$1,550,277 (2014 - \$1,010,320). The weighted average fair value of the share options is \$0.62 (2014 - \$1.23) per share. During the fiscal year ended December 31, 2015, the Company recognized a share-based compensation expense of \$204,594 related to share options with a corresponding increase in contributed surplus.

For the year ended December 31, 2015, expected volatility is based on a review of historical volatilities for the Company.

The expected share option life is based on the employees' historical exercise behaviour.

Notes to Consolidated Financial Statements

December 31, 2015 and December 31, 2014

(expressed in US dollars, unless otherwise noted)

The risk-free interest rate used for each grant is equal to the Canadian treasury bill rates in effect at the date of grant for instruments with a term similar to the expected life of the related share option.

### a) Performance share options

Under the Company's Long-Term Incentive Plan (LTIP), which was adopted in 2013, the Company may issue PSOs to employees, directors and officers in accordance with the Company's 2011 stock option plan (2011 Plan). The purpose of the PSO Plan is to attract, retain and motivate employees of the Company. During the current fiscal year the Company issued 927,978 PSOs in accordance with the provisions of the LTIP resulting in a total of 1,254,247 PSOs outstanding as at December 31, 2015. For the year ended December 31, 2015, the Company determined that the performance hurdles related to the PSOs will not be achieved and as a result no options have vested and the Company did not record any related share-based compensation expense.

### b) Restricted share unit plan

On March 5, 2013, the Board approved the adoption of a RSU Plan as part of the Company's LTIP, which was subsequently approved by shareholders on May 8, 2013. The purpose of the RSU Plan is to attract, retain and motivate employees of the Company. During the current fiscal year, the Company issued 247,912 (2014 - 121,782) RSUs in accordance with the provisions of the RSU Plan. In addition 164,214 RSUs expired resulting in 252,633 RSUs outstanding as at December 31, 2015. For the year ended December 31, 2015, the Company recorded share-based compensation expense of \$129,839 related to RSUs that were issued that vested over three years with no performance hurdles. The Company determined that RSUs which contained performance hurdles had not been achieved and as a result did not record any related share-based compensation expense with respect to these RSUs.

#### c) Deferred share unit plan

On March 5, 2013, the Board approved the adoption of a DSU Plan, which was subsequently approved by shareholders on May 8, 2013. During the fiscal year ended December 31, 2015, 187,974(2014 - 58,750) DSUs were issued to non-employee directors of the Company. During the fiscal year ended December 31, 2015, the Company recognized a share-based compensation expense of \$78,690 related to DSUs with a corresponding increase in contributed surplus. As at December 31, 2015, 123,331 DSUs were outstanding (2014 – 89,025).

Notes to Consolidated Financial Statements

December 31, 2015 and December 31, 2014

(expressed in US dollars, unless otherwise noted)

### 13 Common shares

	Number of common shares	Share Capital \$
Balance - December 31, 2013	56,393,383	492,600,022
Common share options exercised	287,959	43,948
Warrants exercised	202,958	160,058
Common shares repurchased	(406,840)	(762,784)
Balance - December 31, 2014	56,477,460	492,041,244
Common share options exercised	2,798,298	1,140,965
Balance - December 31, 2015	59,275,758	493,182,209

### Share exchange

On November 14, 2014, the Company announced it intended to make a normal course issuer bid (the Bid) to repurchase a certain number of its outstanding common shares through the facilities of the Toronto Stock Exchange. The number of shares to be purchased was not to exceed 2,714,106 common shares. The period of the Bid was between November 21, 2014 and November 20, 2015. The Company did not repurchase any common shares during the year ended December 31, 2015.

### 14 Income taxes

The difference between income tax expense and the income taxes as computed based on the statutory rate is as follows:

	2015	2014
Net loss before income taxes	(14,420,488)	(14,514,589)
Income tax benefit at statutory rate Cost (benefit) resulting from	(3,821,429)	(3,846,366)
Research and development credit Deferred income tax assets expired	(464,066) 193,977	(464,534) 233
Deferred income tax assets not recognized and other	4,091,518	4,310,667

Notes to Consolidated Financial Statements

December 31, 2015 and December 31, 2014

(expressed in US dollars, unless otherwise noted)

Estimated temporary differences in the timing of recognition of expenses for accounting and income tax purposes at December 31 result in deferred income taxes as follows:

	2015	2014
Estimated deferred income tax assets attributable to Net operating loss carry-forwards Research and development credits Other deferred income tax assets	24,477,162 2,576,096 2,298,199	22,865,537 2,447,973 2,176,870
Deferred income tax assets Deferred income tax assets not recognized and other	29,351,457 (29,351,457)	27,490,380 (27,490,380)
Net deferred income tax assets		

The estimated net operating loss carry-forwards and estimated research and development credits expire as follows:

	Canada and the United States of America Netherlands				
	United Sta	United States of America		<u>Canada</u>	
	Net operating loss carry- forwards	Research and development credits	Net operating loss carry- forwards	Research and development credits	
Year ending December 31,					
2015	-	-	8,405	-	
2016	-	-	7,036	-	
2017	-	-	7,626	-	
2018	1,009,887	-	9,939	-	
2019	1,561,172	11,664	11,038	-	
2020	2,063,163	42,132	426,816	-	
2021	2,564,511	55,822	1,065,511	-	
2022	1,338,594	52,731	347,212	-	
2023	1,321,285	44,965	1,957,564	-	
2024	1,532,264	46,333	2,316,405	-	
2025	1,629,456	47,245	-	-	
2026	1,562,856	41,905	415	-	
2027	2,011,361	35,351	-	-	
2028	2,717,038	69,118	2,165	-	
2029	2,854,334	63,226	-	-	
2030	1,207,399	96,302	-	51,074	
2031	3,927,982	-	3,508,318	409,821	
2032	1,127,104	-	3,663,029	706,894	
2033	10,855,247	-	6,738,111	1,017,294	
2034	1,333,972	-	11,961,029	689,206	
2035	2,085,933	-	6,986,379	381,386	
	42,703,558	606,794	39,016,998	3,255,675	

Notes to Consolidated Financial Statements

December 31, 2015 and December 31, 2014

(expressed in US dollars, unless otherwise noted)

### 15 Commitments

The Company has entered into the following financial commitments:

Year ending December 31, 2016	4,034,885
2017	248,625
2018	248,625
2019	248,625
Thereafter	248,625
	5,029,385

During the normal course of operations, the Company may enter into feedstock contracts to secure raw material availability over a 12-month period based on market pricing at the time of purchase. As at December 31, 2015, the Company was committed to purchases of feedstock of approximately \$3,552,117 prior to December 31, 2016.

The Company has a forgivable loan agreement with the Province of Ontario under its Innovation Demonstration Fund Program (Ontario) (IDF), pursuant to which Ontario has provided a forgivable loan up to CA\$3.1 million for a specific technology demonstration project. This loan is forgivable in the event no conditions of default have occurred, the technology is not commercialized outside the Province of Ontario and various other documentation requirements are met. Management has determined that there is reasonable assurance the Company will comply with these conditions.

### 16 Segmented information and enterprise wide disclosures

### Segmented reporting

The Company operates in one reportable segment and generates revenue primarily from the sale of its Ecosphere Biolatex (R) Binders.

### Sales by geographic location

The Company is domiciled in Canada. During the year ended December 31, 2015, revenue from external customers located in Canada was \$2,468,518 (2014 - \$3,296,158). The total revenue from external customers in the following regions is as follows:

	2015	2014
Americas	7,587,160	12,631,831
EMEA	850,717	617,027
Asia Pacific	6,144,943	5,592,887
	14,582,820	18,841,745

Notes to Consolidated Financial Statements

#### December 31, 2015 and December 31, 2014

(expressed in US dollars, unless otherwise noted)

The revenue has been assigned to each jurisdiction, based on the location of the customer. In situations where a sale is made through a reseller, revenue associated with that sale is attributed to the geographic region of the end customer. During the year ended December 31, 2015, revenue attributable to the individual countries representing greater than 10% of total revenues included United States, Japan and Canada, which represented 32%, 32% and 17%, respectively.

During the year ended December 31, 2014, revenue attributable to the individual countries representing greater than 10% of total revenues included United States, Japan and Canada, which represented 42%, 17% and 17%, respectively.

### Sales to major customers

The Company derives a significant portion of its revenues from certain customers. Four customers represented 32%, 19%, 17% and 11% respectively of total revenue for the year ended December 31, 2015 (2014 - three customers represented 23%, 17% and 17% respectively). The concentrations listed do not necessarily apply to the same customer year over year.

### Property, plant and equipment and intangible assets

The Company's property, plant and equipment and intangible assets, reported at their net carrying amount, are located in the following countries:

	2015	2014
Canada	2,641,304	3,046,242
United States of America	3,306,105	4,939,357
The Netherlands	2,798,663	3,757,156
	8,746,072	11,742,755

### 17 Expenses by nature

Additional information on the nature of amounts included in cost of sales, selling, general and administrative and research and development is as follows:

	2015	2014
Wages and salaries, including benefits	5,831,083	9,529,925
Termination benefits	1,939,080	236,473
Share-based compensation	413,123	456,000
Depreciation and amortization	1,445,407	1,767,366
Foreign exchange loss	936,052	-

Notes to Consolidated Financial Statements

December 31, 2015 and December 31, 2014

(expressed in US dollars, unless otherwise noted)

Foreign exchange losses represent the revaluation of monetary assets and liabilities denominated in foreign currencies. The change in foreign exchange revaluation gains and losses is primarily due to foreign exchange rate fluctuations between the US dollar (the Company's functional currency) and foreign currencies and the related impact on the net monetary position in those respective currencies. The foreign exchange losses for the year ended December 31, 2015 primarily relate to monetary assets and liabilities denominated in Canadian dollars.

### 18 Loss per share

Basic loss per share is calculated by dividing the profit attributable to equity holders of the Company by the weighted average number of common shares in issue during the year.

Diluted loss per share is equivalent to basic loss per share, as the consideration of potentially dilutive securities would be anti-dilutive.

### 19 Contingencies and guarantees

In connection with the Company's initial public offering on August 4, 2011, the Company agreed to provide an indemnity to each of the retained interest holders for any: (i) loss of deferral of US income taxes attributable to the execution of the put/call agreement that are incurred by a retained interest holder before the third anniversary of the closing of the offering; (ii) interest and penalties paid that are attributable to any US federal, state or local income tax liability of a retained interest holder that arises as a result of a final determination by any US taxing authority relating to the execution of the put/call agreement (taxes); and (iii) certain reasonable fees, costs and expenses paid by a retained interest holder to defend any demand, claim or notice from a US taxing authority with respect to taxes. The Company's liability under the indemnity will not exceed the indemnity cap, which is determined based on \$2.72 per covered share (which equates to \$0.3885 per common share into which each covered share may be exchanged), representing a maximum liability to the Company under the indemnity of approximately \$4 million. The indemnity will terminate on the fifth anniversary of the closing. The Company has assessed the likelihood of incurring the liability as remote and, accordingly, has not recorded a provision at December 31, 2015.

### 20 Comparative figures

Certain comparative figures have been reclassified to conform to the current period's presentation.